WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

23 June 2017

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland (ENNLFR ES)

20 June 2017

Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients (ENNLFR ES)

UPCOMING EVENTS

  • INVESTORS AND BD
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
20.64 USD
Change (%):
0.41 (2.03%)
BRU
0.94 EUR
Change (%):
0.02 (2.18%)